Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol. Pharmacokinetics and Pharmacodynamics in Healthy Adults : A Randomized Clinical Trial C. Austin Zamarripa, PhD; Tory R. Spindle, PhD; Renuka Surujunarain; Elise M. Weerts, PhD; Sumit Bansal, PhD; Jashvant D. Unadkat, PhD; Mary F. Paine, PhD; Ryan Vandrey, PhD Jama Network Open, 2023, 6, (2), e2254752, 1-15. doi : 10.1001/jamanetworkopen.2022.54752 Key Points Question : Are there acute pharmacokinetic or pharmacodynamic differences between oral ingestion of a Δ9-tetrahydrocannabinol (Δ9-THC)- dominant cannabis extract compared with a cannabidiol (CBD)-dominant extract at the same Δ9-THC dose (20 mg) in healthy adults who use cannabis infrequently? Findings : In this randomized clinical trial including 18 [...]
Lire la suiteMort de Raphael Mechoulam, le « père de la recherche sur le cannabis » en Israël Le scientifique a mené des recherches pionnières sur le cannabis, dont les résultats ont permis à cette substance de passer de la contre-culture au courant dominant Par ANDREW SILOW-CARROLL Times of Israël, 12 mars 2023, 16:20 Le professeur Raphael Mechoulam dans son laboratoire du campus Ein Kerem de l’Université hébraïque, le 1er septembre 2016. (Crédit : Melanie Lidman/Times of Israel) JTA — Au début des années 1960, un scientifique d’origine bulgare nommé Raphael Mechoulam est surpris avec cinq kilogrammes de ce qu’il qualifie « de magnifique haschisch libanais de contrebande » [...]
Lire la suiteNegative experiences of patients using medicinal cannabis : A systematic review of qualitative studies Or Gliksberg, P Talma Kushnir, Sharon R. Sznitman, Shaul Lev-Ran, Silviu Brill, Ben H. Amit, Daniel Feingold PhD, Journal of Clinical Nursing, 2023, 1-12. doi : 10.1111/jocn.16653 Abstract Aims and Objectives : In this study, we systematically reviewed qualitative studies concerning patients' experience with medicinal cannabis (MC) use, to gain insight into the negative effects of MC. Background : Over the past decades, the use of MC for therapeutic purposes has increased. However, there is conflicting and insufficient data on possible negative physiological and psychological effects of MC treatment. Design : A systematic review was [...]
Lire la suiteSupporting Future Cannabis Policy – Developing a Standard Joint Unit : A Brief Back-Casting Exercise. Hugo López-Pelayo, Silvia Matrai, Mercè Balcells-Olivero, Eugènia Campeny, Fleur Braddick, Matthijs G. Bossong, Olga S. Cruz, Paolo Deluca, Geert Dom, Daniel Feingold, Tom P. Freeman, Pablo Guzman, Chandni Hindocha, Brian C. Kelly, Nienke Liebregts, Valentina Lorenzetti, Jakob Manthey, João Matias, Clara Oliveras, Maria Teresa Pons, Jürgen Rehm, Moritz Rosenkranz, Zoe Swithenbank, Luc van Deurse, Julian Vicente, Mike Vuolo, Marcin Wojnar and Antoni Gual Frontiers in Psychiatry, 2021, 12, 675033. doi : 10.3389/fpsyt.2021.675033 The standardization of cannabis doses is a priority for research, policy-making, clinical and harm-reduction interventions and consumer security. Scientists [...]
Lire la suiteCannabinoids and their therapeutic applications in mental disorders Maria Scherma, PhD; Anna Lisa Muntoni, MD; Gernot Riedel, PhD; Walter Fratta, PhD; Paola Fadda, PhD Dialogues in Clinical Neuroscience, 2020, 22, (3), 271-279. doi : 10.31887/DCNS.2020.22.3/pfadda Mental disorders represent a significant public health burden worldwide due to their high prevalence, chronically disabling nature, and substantial impact on quality of life. Despite growing knowledge of the pathological mechanisms that underlie the development of these disorders, a high percentage of patients do not respond to first-line clinical treatments; thus, there is a strong need for alternative therapeutic approaches. During the past half-century, after the identification of the [...]
Lire la suiteFluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects Aviva Breuer, Christeene G. Haj, Manoela V. Fogaça, Felipe V. Gomes, Nicole Rodrigues Silva, João Francisco Pedrazzi, Elaine A. Del Bel, Jaime C. Hallak, José A. Crippa, Antonio W. Zuardi, Raphael Mechoulam, Francisco S. Guimarães PLOS One, 2016, 11, (7), e0158779, 1-19. Doi : 10.1371/journal.pone.0158779 Abstract Cannabidiol (CBD) is a major Cannabis sativa constituent, which does not cause the typical marijuana psychoactivity. However, it has been shown to be active in a numerous pharma- cological assays, including mice tests for anxiety, obsessive-compulsive disorder, depres- sion and schizophrenia. In human [...]
Lire la suiteEditorial: Psychological Aspects of Cannabis Use and Cannabis Use Disorder Daniel Feingold, Eva Hoch, Aviv Weinstein and Wayne Hall Frontiers in Psychiatry, 2021, Volume 12 | Article 789197 doi : 10.3389/fpsyt.2021.789197 Editorial on the Research Topic : Psychological Aspects of Cannabis Use and Cannabis Use Disorder Keywords : cannabis, marijuana, cannabis use disorder, psychology, cognition, emotion An increasing global prevalence of cannabis use has produced increased treatment seeking for Cannabis Use Disorder (CUD) and an increased research effort to identify factors associated with initiation of cannabis use, transitions to regular cannabis use and the onset of CUD (1, 2). The majority of empirical studies focus on biological and [...]
Lire la suiteCannabis and Depression Daniel Feingold, Aviv Weinstein Advances in Experimental medicine and Biology, 2021, 1264, 67-80. In book : "Cannabinoids and Neuropsychiatric Disorders", Aviv Weinstein 's Lab Doi : 10.1007/978-3-030-57369-0_5 Abstract There is a growing body of evidence pointing to the co-occurrence of cannabis use and depression. There is also some evidence that the use of cannabis may lead to the onset of depression; however, strong evidence points to the inverse association; i.e. that depression may lead to the onset or increase in cannabis use frequency. Observational and epidemiological studies have not indicated a positive long-term effect of cannabis use on the course and outcome of [...]
Lire la suiteTHREE NEW STUDIES ON CANNABIS AND PTSD Growing numbers of trauma sufferers are medicating with cannabis and finding it helpful. NATE SELTENRICH 31 décembre 2022 In recent years, psilocybin and MDMA have been explored as potential treatments for post-traumatic stress disorder, but somewhat more quietly so has cannabis. In fact, according to a few quick searches of PubMed, cannabis has a longer and richer association with PTSD in the scientific literature than any psychedelic. Though you wouldn’t know that by reading the headlines. Setting aside for a minute how effective psychedelics may or may not be as breakthrough treatments for PTSD, there’s no doubt that [...]
Lire la suiteAttitudes Toward the Use of Medical Cannabis and the Perceived Efficacy, Side-effects and Risks : A Survey of Patients, Nurses and Physicians Neta HaGani, Sharon Sznitman, Michael Dor, Gil Bar-Sela, Dana Oren, Lilia Margolis-Dorfman, Itay Goor-Aryeh & Manfred S. Green Journal of Psychoactive Drugs, 2021, 1-10. Doi : 10.1080/02791072.2021.2009598 ABSTRACT Gaps between physician and patient perceptions may lead to misunderstandings and mismanage of treatment. There are sparse data about the differences in opinions toward medical cannabis (MC) between patients and health professionals. The aim of this study was to examine the attitudes toward MC, its perceived efficacy, side effects and risk of dependency, among patients, [...]
Lire la suite